美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Eikon Therapeutics

12.55

+1.3912.46%

盤後：12.550.00000.00%16:04 EDT

成交量：55.89萬

成交額：682.40萬

市值：6.78億

市盈率：-2.11

高：12.82

開：11.26

低：11.24

收：11.16

52周最高：17.40

52周最低：7.90

股本：5,398.43萬

流通股本：1,764.80萬

量比：0.77

換手率：3.17%

股息：- -

股息率：- -

每股收益(TTM):-5.9500

每股收益(LYR):-115.2900

淨資產收益率：-125.02%

總資產收益率：-36.19%

市淨率：1.45

市盈率(LYR):-0.11

資料載入中...

總覽公司新聞資訊公告

營收暴增無阻英派藥業繼續虧損：預計上半年減虧三成左右！股價早已破發

深圳商报·读创

Eikon Therapeutics宣佈晚期黑色素瘤Eik1001適應症2/3期試驗Teluride-006進入劑量選擇階段

Eikon Therapeutics宣佈Teluride-008臨床試驗首位患者給藥，Eik1001用於非小細胞肺癌的註冊性II/III期研究正式啓動

新聞稿：Eikon Therapeutics 宣佈任命 Ma. Fatima D. Francisco 加入董事會

Eikon Therapeutics公布2025年第四季度及全年財報同步更新臨床進展與企業動態

BUZZ-隨着 IPO 研究平靜期的結束，由 Perlmutter 支持的 Eikon Therapeutics 股價上漲

美銀全球研究啓動對Eikon Therapeutics的覆蓋給予買入評級及34美元目標價

旗艦企業 Generate Biomedicines 希望在美國 IPO 中獲得 22 億美元估值

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/EIKN/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EIKN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":12.55,"timestamp":1787688000000,"preClose":11.16,"halted":0,"volume":558859,"hourTrading":{"tag":"盘后","latestPrice":12.55,"preClose":12.55,"latestTime":"16:04 EDT","volume":5348,"amount":67117.40000000001,"timestamp":1787688248425,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.12455197132616493,"floatShares":17648000,"shares":53984300,"eps":-5.95,"marketStatus":"盤後交易","change":1.39,"latestTime":"08-25 16:09:07 EDT","open":11.26,"high":12.82,"low":11.24,"amount":6824026,"amplitude":0.141577,"askPrice":14.79,"askSize":300,"bidPrice":10.8,"bidSize":700,"shortable":3,"etf":0,"ttmEps":-5.95,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":11.16,"preHourTrading":{"tag":"盘前","latestPrice":11.83,"preClose":11.16,"latestTime":"09:25 EDT","volume":54,"amount":638.82,"timestamp":1787664300069,"change":0.67,"changeRate":0.060036,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":12.55,"preClose":12.55,"latestTime":"16:04 EDT","volume":5348,"amount":67117.40000000001,"timestamp":1787688248425,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.766484},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","floatShares":17648000,"roa":"-36.19%","roe":"-125.02%","lyrEps":-115.29,"volumeRatio":0.766484,"shares":53984300,"dividePrice":0,"high":12.82,"amplitude":0.141577,"preClose":11.16,"low":11.24,"week52Low":7.9,"pbRate":"1.45","week52High":17.4,"institutionHeld":0,"latestPrice":12.55,"committee":0.4,"eps":-5.95,"divideRate":0,"volume":558859,"delay":0,"ttmEps":-5.95,"open":11.26,"prevYearClose":18,"prevWeekClose":11.39,"prevMonthClose":9.21,"prevQuarterClose":13.05,"fiveDayClose":11.65,"twentyDayClose":9.49,"sixtyDayClose":10.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EIKN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"EIKN","fiscalQuarterEnding":"2026/06","expectedEps":-1.61,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.63},{"market":"US","date":"2026-05-11","symbol":"EIKN","fiscalQuarterEnding":"2026/03","expectedEps":-1.47,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-2.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EIKN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EIKN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0,"sell":0,"strongSell":0.1667,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1775102400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EIKN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EIKN","date":"2026-08-24","current":-2.07563,"percent":0.360294,"low":-3.139466,"twenty":-2.100934,"median":-1.723362,"eighty":-1.535213,"high":-1.335246,"avg":-1.859596,"sd":0.391079,"marketCap":616939691},"quantilePoints":[{"date":"2026-02-06","current":-2.616222,"twenty":-3.034817,"median":-2.877844,"eighty":-2.720871,"marketCap":809765055},{"date":"2026-02-13","current":-2.586571,"twenty":-2.610292,"median":-2.537735,"eighty":-2.527619,"marketCap":800587717},{"date":"2026-02-20","current":-2.703429,"twenty":-2.7418,"median":-2.616222,"eighty":-2.529014,"marketCap":836757223},{"date":"2026-02-27","current":-2.379017,"twenty":-2.703429,"median":-2.596164,"eighty":-2.52727,"marketCap":736346356},{"date":"2026-03-06","current":-2.535991,"twenty":-2.644128,"median":-2.595292,"eighty":-2.523782,"marketCap":784932259},{"date":"2026-03-13","current":-2.054606,"twenty":-2.624942,"median":-2.562153,"eighty":-2.406924,"marketCap":635935489},{"date":"2026-03-20","current":-1.915074,"twenty":-2.616222,"median":-2.529014,"eighty":-2.298787,"marketCap":592748020},{"date":"2026-03-27","current":-1.836588,"twenty":-2.600524,"median":-2.515933,"eighty":-2.054606,"marketCap":568455068},{"date":"2026-04-02","current":-1.678228,"twenty":-2.599129,"median":-2.426109,"eighty":-1.985189,"marketCap":544162116},{"date":"2026-04-10","current":-1.504368,"twenty":-2.597385,"median":-2.379017,"eighty":-1.821565,"marketCap":487788380},{"date":"2026-04-17","current":-1.876704,"twenty":-2.595641,"median":-2.269137,"eighty":-1.751381,"marketCap":608517358},{"date":"2026-04-24","current":-1.786542,"twenty":-2.595292,"median":-2.061583,"eighty":-1.769507,"marketCap":579282538},{"date":"2026-05-01","current":-1.605383,"twenty":-2.588315,"median":-2.045013,"eighty":-1.651966,"marketCap":520542206},{"date":"2026-05-08","current":-1.531083,"twenty":-2.547502,"median":-1.986901,"eighty":-1.641614,"marketCap":496450549},{"date":"2026-05-15","current":-2.105086,"twenty":-2.53634,"median":-1.963159,"eighty":-1.651966,"marketCap":713546154},{"date":"2026-05-22","current":-1.782455,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"marketCap":604186273},{"date":"2026-05-29","current":-1.645097,"twenty":-2.527968,"median":-1.929027,"eighty":-1.650964,"marketCap":557627116},{"date":"2026-06-05","current":-1.562046,"twenty":-2.525177,"median":-1.895889,"eighty":-1.633553,"marketCap":529475781},{"date":"2026-06-12","current":-1.360801,"twenty":-2.514363,"median":-1.841551,"eighty":-1.597703,"marketCap":461261110},{"date":"2026-06-18","current":-1.55406,"twenty":-2.482968,"median":-1.809917,"eighty":-1.567693,"marketCap":526768850},{"date":"2026-06-26","current":-1.573226,"twenty":-2.429947,"median":-1.776985,"eighty":-1.53713,"marketCap":533265485},{"date":"2026-07-02","current":-1.95655,"twenty":-2.406226,"median":-1.79823,"eighty":-1.541282,"marketCap":663198193},{"date":"2026-07-10","current":-1.79204,"twenty":-2.398552,"median":-1.809917,"eighty":-1.555657,"marketCap":607435406},{"date":"2026-07-17","current":-1.589198,"twenty":-2.377273,"median":-1.784498,"eighty":-1.563963,"marketCap":538679348},{"date":"2026-07-24","current":-1.536491,"twenty":-2.355995,"median":-1.761474,"eighty":-1.543838,"marketCap":520813601},{"date":"2026-07-31","current":-1.536491,"twenty":-2.298787,"median":-1.731347,"eighty":-1.536491,"marketCap":520813601},{"date":"2026-08-07","current":-1.471006,"twenty":-2.239486,"median":-1.715581,"eighty":-1.534894,"marketCap":498616763},{"date":"2026-08-14","current":-1.736786,"twenty":-2.116266,"median":-1.712181,"eighty":-1.534894,"marketCap":559524759},{"date":"2026-08-21","current":-1.807401,"twenty":-2.105086,"median":-1.719889,"eighty":-1.534894,"marketCap":582274072},{"date":"2026-08-24","current":-1.915004,"twenty":-2.100934,"median":-1.723362,"eighty":-1.535213,"marketCap":616939691}],"updateTime":1787678752686},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EIKN\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658911994","title":"營收暴增無阻英派藥業繼續虧損：預計上半年減虧三成左右！股價早已破發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911994","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658911994?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 23:03","pubTimestamp":1786460583,"startTime":"0","endTime":"0","summary":"8月11日，英派药业(07630.HK)发布盈利预告，公司预计2026年上半年收入约9470万元至1.16亿元，较去年同期约2520万元增长约276%至359%；预计期内亏损约8170万元至9990万元，较去年同期约1.29亿元减少约22%至37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113838249182.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113838249182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4139","07630","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143932807","title":"Eikon Therapeutics宣佈晚期黑色素瘤Eik1001適應症2/3期試驗Teluride-006進入劑量選擇階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1143932807","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143932807?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 19:31","pubTimestamp":1786447878,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics今日对外披露，其针对晚期黑色素瘤开展的在研药物Eik1001，已正式进入一项名为Teluride-006的适应性2/3期临床试验的剂量选择阶段。这一里程碑标志着该研究方案向前迈出了关键一步。Eikon Therapeutics专注于开发创新疗法，以攻克难治性癌症。此次剂量选择的宣布，体现了公司对于严谨临床试验流程的坚守，以及对加速推进Eik1001临床开发进度的决心。市场分析人士正密切关注这一进展，因为若试验结果积极，Eik1001有望为晚期黑色素瘤患者群体带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181280733","title":"Eikon Therapeutics宣佈Teluride-008臨床試驗首位患者給藥，Eik1001用於非小細胞肺癌的註冊性II/III期研究正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1181280733","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181280733?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 19:32","pubTimestamp":1785151940,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics今日宣布，其在研药物Eik1001的注册性II/III期临床试验——Teluride-008，已完成首位患者给药。这项研究专注于非小细胞肺癌（NSCLC）的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116184350","title":"新聞稿：Eikon Therapeutics 宣佈任命 Ma. Fatima D. Francisco 加入董事會","url":"https://stock-news.laohu8.com/highlight/detail?id=1116184350","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116184350?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 20:04","pubTimestamp":1780920252,"startTime":"0","endTime":"0","summary":"加州米尔布雷，2026年6月8日——致力于开发创新药物以解决严重未满足医疗需求的后期临床生物制药公司 Eikon Therapeutics, Inc.  今日宣布，任命 Ma. FatimaD. Francisco 女士为公司董事会独立董事，自2026年6月15日起生效。Francisco 女士还将担任董事会薪酬委员会成员。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198302033","title":"Eikon Therapeutics公布2025年第四季度及全年財報 同步更新臨床進展與企業動態","url":"https://stock-news.laohu8.com/highlight/detail?id=1198302033","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198302033?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 19:49","pubTimestamp":1774871395,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics近日正式披露2025年第四季度及全年财务业绩报告，同时就核心临床项目进展与公司战略规划进行同步更新。此次公告全面呈现了公司在财务表现、研发管线及运营层面的最新态势。此次综合更新不仅彰显了Eikon Therapeutics以技术驱动创新的发展路径，也反映出其通过跨学科平台加速药物发现的长期承诺。公司表示将继续推进临床阶段项目的全球化布局，同时加强财务稳健性以支持未来增长计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616505273","title":"BUZZ-隨着 IPO 研究平靜期的結束，由 Perlmutter 支持的 Eikon Therapeutics 股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2616505273","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616505273?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 02:10","pubTimestamp":1772475022,"startTime":"0","endTime":"0","summary":"3月2日 - ** 默克公司资深员工珀尔穆特领导的药物开发商Eikon TherapeuticsEIKN.O股价上涨3.9%至14.31美元。** 随着首次公开募股研究平静期的结束，至少有三家华尔街券商开始给予看涨评级** 摩根大通表示：\"EIKN 的投资组合以 Keytruda 前开发者为首，具有战略定位，通过内授权拥有两项先进资产，并通过其超分辨率显微镜发现引擎建立了自己的管线。** EIKN 上个月在纽约上市 ，首次公开募股定价为每股 18 美元， ，共售出 2120 万股。** 截至上次收盘，EIKN 股价自二月上市以来下跌了 23%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL4S3ZQ1UU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0070302665.USD","SG9999002232.USD","LU2125154778.USD","LU2468319806.SGD","IE0009355771.USD","IE0034235188.USD","LU0211331839.USD","LU1037948897.HKD","LU1668664300.SGD","LU1989772840.SGD","LU2265009873.SGD","LU0170899867.USD","LU1267930227.SGD","IE00BN8TJ469.HKD","LU0971096721.USD","LU1037948541.HKD","LU1162221912.USD","LU1035773651.USD","LU1880398471.USD","LU1430594728.SGD","LU1894683264.USD","BK4504","LU2324357040.USD","LU1069347547.HKD","LU1066051498.USD","LU0310800965.SGD","LU0683600562.USD","LU2023250504.SGD","LU1366192091.USD","EIKN","LU0320765489.SGD","IE00BBT3K403.USD","LU2023250843.SGD","LU0149725797.USD","LU0306806265.USD","LU0006306889.USD","LU1941712264.USD","IE00BZ1G4Q59.USD","LU0477156953.USD","LU1718418525.SGD","LU0477156797.USD","LU1280957306.USD","LU1066053197.SGD","LU0122379950.USD","LU1917777945.USD","SG9999014542.SGD","LU0965508806.USD","LU0208291251.USD","LU0965509101.SGD","LU0289739699.SGD","IE00B1BXHZ80.USD","LU2461242641.AUD","IE00BSNM7G36.USD","LU0985320562.USD","LU0256863902.USD","BK4139","IE00BLSP4452.SGD","SG9999001440.SGD","LU0203347892.USD","LU1061106388.HKD","BK4588","LU1929549753.HKD","LU2112291526.USD","IE0002141913.USD","BK4550","BK4533","LU0648000940.SGD","LU0306807586.USD","LU0965509010.AUD","LU1201861165.SGD","LU1496350502.SGD","LU0128525689.USD","LU0861579265.USD","IE00BKVL7J92.USD","LU2106854487.HKD","SG9999001176.USD","LU1023059063.AUD","LU1983299246.USD","IE00B19Z3B42.SGD","LU0106261372.USD","LU0203345920.USD","BK4516","LU1201861249.SGD","SG9999002224.SGD","IE000M9KFDE8.USD","LU1057294990.SGD","LU1496350171.SGD","SG9999013999.USD","BK4534","LU1093756325.SGD","LU1066051811.HKD","SGXZ57979304.SGD","LU1506573853.SGD","LU1934455277.USD","SG9999014575.USD","LU0320765646.SGD","SG9999014559.SGD","SG9999015358.SGD","LU2361044865.SGD","LU0965509283.SGD","LU1291159041.SGD","LU0648001328.SGD","LU1093756168.USD","LU0321505868.SGD","LU2361044949.HKD","LU1074936037.SGD","LU0265550946.USD","LU1066051225.USD","LU0058720904.USD","LU0868494617.USD","LU0640476718.USD","LU1571399168.USD","LU1880398554.USD","IE00B7SZLL34.SGD","SG9999014567.USD","SG9999015341.SGD","LU1934455863.HKD","LU1974910355.USD","LU2129689431.USD","LU1699723380.USD","LU0052756011.USD","LU0130102774.USD","LU2129689514.USD","LU0130517989.USD","LU0787776722.HKD","LU1804176565.USD","LU0256863811.USD","LU0321505439.SGD","LU0980610538.SGD","BK4559","LU0130103400.USD","BK4007","BK4553","IE0002270589.USD","LU1989772923.USD","LU2361045086.USD","LU1585245621.USD","LU0106831901.USD","IE00BJT1NW94.SGD","LU0417517546.SGD","LU1934455194.USD","BK4581","LU0234570918.USD","BK4585","LU1883839398.USD","IE00BJJMRZ35.SGD","LU2133065610.SGD","LU0130518102.USD","LU1116320737.USD","LU0432979614.USD","IE00BLSP4239.USD","LU0265550359.USD","IE00B19Z3581.USD","LU1116320901.HKD","LU0098860793.USD","IE00BFXG1179.USD","LU0234572021.USD","SG9999001176.SGD","LU2129689605.HKD","LU0238689110.USD","IE00BFTCPJ56.SGD","LU0266013472.USD","LU0053666078.USD","LU2125154935.USD","LU2089984988.USD","LU1941712348.USD","LU1989771016.USD","LU2360032135.SGD","IE0001KFT4U8.USD","IE00B4R5TH58.HKD","LU0314106906.USD","BK4207","LU1363072403.SGD","LU1791807156.HKD","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136724466","title":"美銀全球研究啓動對Eikon Therapeutics的覆蓋 給予買入評級及34美元目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=1136724466","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136724466?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 19:43","pubTimestamp":1772451794,"startTime":"0","endTime":"0","summary":"美银全球研究近日宣布，正式启动对生物科技公司Eikon Therapeutics（股票代码：EIKN）的研究覆盖，并首次给予\"买入\"评级。该机构同时设定了34美元的目标股价，显示出对该公司未来增长前景的积极预期。\n此次覆盖启动标志着华尔街主要机构对Eikon Therapeutics在创新药物开发领域技术实力的认可。分析师在报告中指出，公司独特的平台技术和研发管线布局为其长期价值提升奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613789435","title":"旗艦企業 Generate Biomedicines 希望在美國 IPO 中獲得 22 億美元估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2613789435","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613789435?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 19:54","pubTimestamp":1771847674,"startTime":"0","endTime":"0","summary":"更新版 3-旗舰企业 Generate Biomedicines 希望在美国 IPO 中获得 22 亿美元估值在第 3、6、7 段添加分析师评论Arasu Kannagi Basil路透2月23日 - 药物开发商Generate Biomedicines周一表示，该公司在美国首次公开募股的目标估值将高达21.7亿美元，从而进入上市步伐加快的生物技术市场。Aktis Oncology AKTS.O、Agomab Therapeutics AGMB.O、Veradermics MANE.N、Eikon Therapeutics EIKN.O和SpyGlass Pharma SGP.O今年已经登陆美国资本市场。\"Generate公司用于治疗严重哮喘的主要候选产品GB-0895正在进行后期试验。预计这项研究将于 2028 年上半年全部完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4S3ZJ0Q2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU2750360641.GBP","LU1868836757.USD","LU2471134796.USD","BK4127","LU0889565916.HKD","LU2028103732.USD","GSX","LU0795875169.SGD","BK4534","MRNY","IE00BKVL7J92.USD","IE0004091025.USD","LU0096364046.USD","BK4550","LU1868836914.USD","LU2750360997.AUD","AGMB","EIKN","LU0251142724.SGD","LU0320765992.SGD","LU1162221912.USD","LU2237443622.USD","IE00BJJMRZ35.SGD","AMGN","LU0098860793.USD","LU0234570918.USD","LU1804176565.USD","MANE","AKTS","LU0122379950.USD","LU2237443465.HKD","LU2133065610.SGD","LU1244550494.USD","BK4516","LU1791807156.HKD","BK4139","LU2089283258.USD","BK4566","IE00B2B36J28.USD","LU0912757837.SGD","MRNX","LU2265009873.SGD","PIPR","LU0106261372.USD","LU2111349929.HKD","SGP","MRNA","BK4552","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}